Prof Mohamad Mohty speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about what is being discussed in multiple myeloma at EHA 2019.
He believes that the use of monoclonal antibodies have been a real highlight from this meeting and names the CASSIOPEIA and COLUMBA trials as showing important data.
Prof Mohty also discusses bispecific antibodies, with a study showing a very high rate of response from treatment with AMG 420.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.